Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several recent trials indicate low-dose ketamine produces rapid antidepressant effects. However, uncertainty remains in several areas: dose response, consistency across patient groups, effects on suicidality, and possible biases arising from crossover trials. METHODS: A systematic search was conducted for relevant randomized trials in Medline, Embase, and PsycINFO databases up to August 2014. The primary endpoints were change in depression scale scores at days 1, 3 and 7, remission, response, suicidality, safety, and tolerability. Data were independently abstracted by 2 reviewers. Where possible, unpublished data were obtained on treatment effects in the first period of crossover trials. RESULTS: Nine trials were identified, including 201 patients (52% female, mean age 46 years). Six trials assessed low-dose ketamine (0.5 mg/kg i.v.) and 3 tested very low-dose ketamine (one trial assessed 50 mg intra-nasal spray, another assessed 0.1-0.4 mg/kg i.v., and another assessed 0.1-0.5 mg/kg i.v., intramuscular, or s.c.). At day 3, the reduction in depression severity score was less marked in the very low-dose trials (P homogeneity <.05) and among bipolar patients. In analyses excluding the second period of crossover trials, response rates at day 7 were increased with ketamine (relative risk 3.4, 95% CI 1.6-7.1, P=.001), as were remission rates (relative risk 2.6, CI 1.2-5.7, P=.02). The absolute benefits were large, with day 7 remission rates of 24% vs 6% (P=.02). Seven trials provided unpublished data on suicidality item scores, which were reduced on days 1 and 3 (both P<.01) but not day 7. CONCLUSION: Low-dose ketamine appears more effective than very low dose. There is substantial heterogeneity in clinical response, with remission among one-fifth of patients at 1 week but most others having benefits that are less durable. Larger, longer term parallel group trials are needed to determine if efficacy can be extended and to further assess safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine, a glutamatergic agent used routinely for induction and maintenance of anesthesia, exhibits well-replicated, rapid, potent antidepressant effects in randomized controlled trials (i.e., metaanalytic Cohen's d=1.4, a large effect) 12 , even in difficult-to-treat conditions such as treatment-resistant depression 32 and bipolar depression 33 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Approach: Intravenous ketamine Evidence: Strong support 12”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As an example, we discuss the potential for ketamine-which exhibits both rapid plasticity-enhancing effects in animal models 4,10 and rapid clinical effects in human patients 11,12 -to provide a test of the predictions of this integrative model, including simultaneous and correlated reversals of multiple plasticity-related deficits across levels of analysis.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258 · cited 2×
“…or even enhanced by repeated dosing, such as the 2 to 3 times weekly schedule that has been assessed in some case series with promising findings (Price et al., 2009; aan het Rot et al., 2010; DiazGranados et al., 2010b; Larkin and Beautrais, 2011; Rasmussen et al., 2013; Shiroma et al., 2014).”
BackgroundRetractedHamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 4×
“The primary endpoint was change in depression severity scores from baseline on depression scales such as the Hamilton Depression Rating Scale (HAM-D; Hamilton, 1960) and/or the Montgomery Åsberg Depression Rating Scale [MADRS]) at the following times: day 1 (24 hours after first dose), day 3, and day 7.”
MethodInfluentialCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 3×
“The I2 statistic was used to assess heterogeneity of trial results, and subgroup heterogeneity was tested using a chi-squared statistic (Higgins and Green, 2009).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 3×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al., 1978), and Clinician Administered Disso…”
MethodA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 3×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al., 1978), and Clinician Administered Disso…”
MethodMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 8×
“The results showed that Visual Analogue Scale score for intoxication “high” scores returned to baseline within 110 minutes of the infusion (Berman et al., 2000).”
BackgroundMethodResultInfluentialA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“Several additional strands of evidence indicate that the benefit observed in these trials is a result of depression treatment, rather than nonspecific mood elevation or a ‘high’ following ketamine administration: there is improvement in core depressive symptoms such as sadness, suicidality, and helplessness; the time…”
Background
Research works printed but not linked: 2
- Aitken, 1969, Measurement of feelings using visual analogue scales, Proc R Soc Med, 62, 989
- RevMan (2014) The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Cited by
Items 201–226 of 226
Ketamina eta esketaminaren erabilera depresioerresistentea tratatzeko: etorkizunerako erronkak
Elexpe, A., Bruzos-Cidón, C., Cabrera, M., Barreda‐Gómez, G., & Torrecilla, M. (2020) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.21862
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
Loo, C. K. A., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P. B., Glue, P., Sarma, S., Gálvez, V., Hadži-Pavlović, D., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4107711 · Cited by 1
Self-citationZanella, G. T., Vieira, F., Locatelli, G. M., Verardi, A. D., & Olsson, D. C. (2016) · Enciclopédia Biosfera · doi:10.18677/enciclopedia_biosfera_2016_077
Serafini, G., Hayley, S. P., Ghasemi, M., & Amore, M. (2017) · Wiley eBooks · doi:10.1002/9783527803781.ch11
Ready, Set, Action: Potential Breakthrough Therapy for Treatment-Resistant Depression
Garlejo, A. (2017) · USF Scholarship Repository (University of San Francisco)
Neuroimmunopharmacology at the Interface of Inflammation and Pharmacology Relevant to Depression
Holmes, J., Corrigan, F., & Hutchinson, M. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00012-x
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 2
KETAMINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER AND ITS POTENTIAL FOR ABUSE
Freitas, D. V., Fernandes, C. P., Teixeira, R. J., Soares, C., Carneiro, S., & Jorge, B. (2019) · doi:10.26226/morressier.5d1a035857558b317a13f645
Current Treatments for Depression
Krystal, J. H., & Charney, D. S. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0031
Reissmann, S., Hartmann, M., Kist, A., Liechti, M. E., & Stocker, K. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1197697 · Cited by 2
Pham, G. S., & Mathew, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00014-8
The effectiveness of ketamine in medication of treatment-resistant depression - review
Brzozowska, P., Bulska, K., Sławek, K., Piela, A., Piotrowski, J., Hądzlik, I., Biały-Karbowniczek, J., Nowińska, B., Łuczak, B., & Słychan, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52628
“Lower doses should probably be considered ineffective [22].”
BackgroundREVOLUTIONIZING DEPRESSION TREATMENT: A PARADIGM SHIFT OF KETAMINE THERAPY – A SYSTEMATIC REVIEW
Kaushal, Y., GOYAL, P., & Sehgal, A. (2024) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2024v17i8.51360
CETAMINA COMO INTERVENÇÃO TERAPÊUTICA NA DEPRESSÃO PSICÓTICA E DEPRESSÃO REFRATÁRIA A TRATAMENTO
dos Santos, P. P., Silvério, A. P., Ribeiro, B. C., Rodrigues, L. C., & Nunes, Y. T. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i8.5624
Current Treatments for Depression
Fava, M., & Krystal, J. H. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0034
Ketamine for unipolar major depression: critical examination of antidepressant effects
Patel, A. (2025) · BJPsych Advances · doi:10.1192/bja.2024.84
Practical approaches to cardiac clearance in nontraditional clinical scenarios
Kramer, E. F., Ricci, J. F., Shukla, K., Blaker, N. J., Shroff, S., Brand, S. J., Khasawneh, T., Sreekanth, S., & Winchester, D. E. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.07.017
McNaughton, N., Shadli, S. M., Beaglehole, B., & Glue, P. (2026) · Journal of the Royal Society of New Zealand · doi:10.1002/snz2.70002 · Cited by 1
“The first report of an effect of ketamine on TR depression (Berman et al. 2000) has been extensively replicated (Xu et al. 2016) and potentially extended to OCD (Rodriguez et al. 2013; Beaglehole et al. 2025a) and PTSD (Feder et al. 2014; Beaglehole et al. 2025b).”
Self-citationSympathetic activation but not dissociation linked to ketamine’s sustained antidepressant effect
Andrashko, V., Novak, T., Kopeček, M., Šuláková, A., Knop, V., & Horacek, J. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261419636
“53 Throughout the administration and for at least 30 min after the infusion, all patients were in a relaxed semi-reclining position in a room with reduced noise and dimmed lighting, accompanied by quiet non-lyrical relaxing music and under continuous medical supervision.”
Atídio, J. P., Delfino, R. S., Garios, I. S., de Brito, C. S. G. F., Gerheim, Y. P., Vasconcelos, G. M. D. A. E., Piloto, R., Ferro, M. D., Júnior, R. O. P. D. S., Surjan, J. C., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121721
Prise en charge médicamenteuse des patients souffrant de douleur chronique réfractaire
Corriger, A. (2019) · theses.fr (ABES) · doi:10.70675/668e4777zf8d0z4bdcz9780z0f91fedfe2b6
Depresyon Tanıdan Tedaviye Klinik Süreç
Gül, V. (2026) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.4140
Carter, G., Hackett, M. L., Nikolin, S., Dong, V., Glozier, N., Sarma, S., Martin, D. M., Berk, M., Gálvez, V., Somogyi, A. A., et al. (2026) · Archives of Suicide Research · doi:10.1080/13811118.2026.2669779
Self-citationGlozier, N., Morris, R. W., Stratton, E., Somogyi, A. A., Sarma, S., Rodgers, A., Gálvez, V., Nikolin, S., Mitchell, P. B., Mills, N. T., et al. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10692
Self-citation
Metadata
- Authors
- Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., Mitchell, P. B., & Rodgers, A.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Loo, Colleen
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-17
- Volume
- 19
- Issue
- 4
- Pages
- pyv124
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4851268
- OpenAlex
- W2197394318
- Cited by
- 226
- References
- 44
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 22 · 2023: 22 · 2022: 22 · 2021: 20 · 2020: 29 · 2019: 26 · 2018: 28 · 2017: 24 · 2016: 13
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Figshare (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Institute of Mental Health (K23MH104465)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, major depressive disorder, low-dose ketamine, rapid antidepressant effects, dose-response relationship, remission, response rate, suicidality, bipolar disorder, crossover trial, safety and tolerability
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.